Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 5, 2003, Pages 1363-1373

  Azria, David ^a,b,c   Dorvillius, Mylène ^a,b   Gourgou, Sophie ^c   Martineau, Pierre ^c   Robert, Bruno ^a,b   Pugnière, Martine ^c   Delard, René ^c   Ychou, Marc ^a,b,c   Dubois, Jean Bernard ^a,b,c   Pèlegrin, André ^a,b,d  

^a INSERM   (France)

^b CNRS   (France)

^c CENTRE VAL D AURELLE   (France)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Additivity; Bispecific antibody; CEA expressing digestive cancers; Radiotherapy enhancement; Tumor necrosis factor alpha

Indexed keywords

ANTIBODIES; ANTIGENS; TOXICITY; TUMORS;

SYSTEMIC SIDE EFFECTS;

RADIOTHERAPY;

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL LINE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION;

EID: 0037377050     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00013-0     Document Type: Article

References (46)

1. Talmadge J.E., Herberman R.B. The preclinical screening laboratory Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep. 70:1986;171-182.
2. Dubois J.B., Serrou B. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guerin. Cancer Res. 36:1976;1731-1734.
3. Sugarman B.J., Aggarwal B.B., Hass P.E., et al. Recombinant human tumor necrosis factor-alpha Effects on proliferation of normal and transformed cells in vitro. Science. 230:1985;943-945.
4. Asher A., Mule J.J., Reichert C.M., et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 138:1987;963-974.
5. Abbruzzese J.L., Levin B., Ajani J.A., et al. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 49:1989;4057-4061.
6. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 72:1975;3666-3670.
7. Beutler B., Cerami A. The history, properties, and biological effects of cachectin. Biochemistry. 27:1988;7575-7582.
8. Old LJ. Tumor necrosis factor. Sci Am 1988;258:59-60, 69-75.
9. Helson L., Helson C., Green S. Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol. 47:1979;53-60.
10. Yamauchi N., Kuriyama H., Watanabe N., et al. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res. 49:1989;1671-1675.
11. Zimmerman R.J., Chan A., Leadon S.A. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res. 49:1989;1644-1648.
12. Rubin B.Y., Smith L.J., Hellermann G.R., et al. Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res. 48:1988;6006-6010.
13. Langley R.E., Palayoor S.T., Coleman C.N., et al. Modifiers of radiation-induced apoptosis. Radiat Res. 136:1993;320-326.
14. Yamada T., Ohyama H. Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int J Radiat Biol Relat Stud Phys Chem Med. 53:1988;65-75.
15. Kimura K., Bowen C., Spiegel S., et al. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 59:1999;1606-1614.
16. Gridley D.S., Glisson W.C., Uhm J.R. Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Ther Immunol. 1:1994;25-31.
17. Hallahan D.E., Beckett M.A., Kufe D., et al. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys. 19:1990;69-74.
18. Nishiguchi I., Willingham V., Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys. 18:1990;555-558.
19. Sersa G., Willingham V., Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer. 42:1988;129-134.
20. Gridley D.S., Archambeau J.O., Andres M.A., et al. Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res. 9:1997;217-227.
21. Moritz T., Niederle N., Baumann J., et al. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother. 29:1989;144-150.
22. Havell E.A., Fiers W., North R.J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med. 167:1988;1067-1085.
23. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 10:1992;52-60.
24. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 10:1998;573-580.
25. Mavligit G.M., Zukiwski A.A., Charnsangavej C., et al. Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer. 69:1992;557-561.
26. van der Schelling G.P., IJzermans J.N., Kok T.C., et al. A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor. Eur J Cancer. 28:1992;1073-1078.
27. Robert B., Mach J.P., Mani J.C., et al. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res. 56:1996;4758-4765.
28. Tom B.H., Rutzky L.P., Jakstys M.M., et al. Human colonic adenocarcinoma cells I. Establishment and description of a new line. In Vitro. 12:1976;180-191.
29. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy The concept of additivity. Int J Radiat Oncol Biol Phys. 5:1979;85-91.
30. Steel G.G. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys. 5:1979;1145-1150.
31. Kano Y., Ohnuma T., Okano T., et al. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 48:1988;351-356.
32. Old L.J. Tumor necrosis factor (TNF). Science. 230:1985;630-632.
33. Sherman M.L., Spriggs D.R., Arthur K.A., et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients Phase I toxicity and effects on lipid metabolism. J Clin Oncol. 6:1988;344-350.
34. Chapman P.B., Lester T.J., Casper E.S., et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 5:1987;1942-1951.
35. Manetta A., Lucci J., Soopikian J., et al. In vitro cytotoxicity of human recombinant tumor necrosis factor alpha in association with radiotherapy in a human ovarian carcinoma cell line. Gynecol Oncol. 38:1990;200-202.
36. Matthews N., Neale M.L., Jackson S.K., et al. Tumour cell killing by tumour necrosis factor Inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology. 62:1987;153-155.
37. Repine J.E., Pfenninger O.W., Talmage D.W., et al. Dimethyl sulfoxide prevents DNA nicking mediated by ionizing radiation or iron/hydrogen peroxide-generated hydroxyl radical. Proc Natl Acad Sci U S A. 78:1981;1001-1003.
38. Dinarello C.A., Cannon J.G., Wolff S.M., et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 163:1986;1433-1450.
39. Ostensen M.E., Thiele D.L., Lipsky P.E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol. 138:1987;4185-4191.
40. Talmadge J.E., Tribble H.R., Pennington R.W., et al. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 47:1987;2563-2570.
41. Cavender D., Saegusa Y., Ziff M. Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J Immunol. 139:1987;1855-1860.
42. Gamble J.R., Harlan J.M., Klebanoff S.J., et al. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 82:1985;8667-8671.
43. Sato N., Goto T., Haranaka K., et al. Actions of tumor necrosis factor on cultured vascular endothelial cells Morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst. 76:1986;1113-1121.
44. Ruegg C., Yilmaz A., Bieler G., et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 4:1998;408-414.
45. Gridley D.S., Hammond S.N., Liwnicz B.H. Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts. Anticancer Res. 14:1994;1107-1112.
46. Gupta V.K., Park J.O., Jaskowiak N.T., et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 9:2002;500-504.